ECMO therapy helps avoid lung transplant in COVID patients: Apollo Doc

By using ECMO we have seen that the majority of patients with significant lung injury recover fully, eliminating the need for a lung transplant, according to media Dr. Paul Ramesh, Senior Consultant Cardiothoracic and Heart and Lung Transplant Surgeon, Apollo Hospitals.ECMO treatment involves the purification of blood and oxygenation through large tubes placed inside large veins (close to the heart) and returned back by means of a pump.


In the majority of patients who have COVID-19 that causes lung failure, only lung support is required. In a small number of patients, it is required for the support of the heart function also.

In a media communication on the subject Apollo Hospitals Chennai, ECMO unit has set the longest bridge to lung recovery patients on ECMO for 116 days (183 days of hospitalization).


Sharing insights with the media Dr. Paul Ramesh, Senior Consultant Cardiothoracic and Heart and Lung Transplant Surgeon, Apollo Hospitals, said “The average period on ECMO prior to discharge is 60 days.


The current survival rate (at 6 months) for ECMO patients is 73.9 percent, which is higher than the global average of 40-50 percent.


One of the most effective outcomes of Apollo Hospitals’ ECMO program is a patient who was on ECMO for 116 days, the longest bridge to recovery in India. By using ECMO we have seen that the majority of patients with significant lung injury recover fully, eliminating the need for a lung transplant.”

Leave a Reply

Your email address will not be published. Required fields are marked *